Sponsor the Meeting
Interested in gaining extensive marketing exposure and access to the advanced therapies industry? Contact Laura Parsons at email@example.com for full sponsorship information for the 2015 Stem Cell Meeting on the Mesa.
BioLife Solutions develops, manufactures and markets biopreservation media and high performance thermal packaging products for cells, tissues and organs. The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery and regenerative medicine markets. BioLife’s products are serum-free and protein-free, fully defined and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues and organs. www.biolifesolutions.com
The Cell Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 100 employees focusing on cell and gene therapy technologies, we work with our partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. We offer leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. We aim to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. Regenerative medicine is one of the UK government’s eight great technologies that support UK science strengths and business capabilities. The Cell Therapy Catapult is part-funded by Innovate UK, formerly the Technology Strategy Board – the UK’s innovation agency. www.ct.catapult.org.uk | www.gov.uk/innovate-uk
Mesoblast Limited is developing novel biotherapeutics derived from its proprietary adult stem cell-based technologies. The Company’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs. Its strategic product development focus is in four major and distinct areas – systemic inflammatory conditions, cardiovascular diseases, orthopedic diseases of the spine and oncology conditions. Mesoblast’s corporate strategy is to leverage proprietary cell-based and complementary biologic technologies to develop products for unmet medical needs; bring multiple products to market within a parallel timeframe; underpin future financial growth through investing in manufacturing operations; and enhance the likelihood of commercial success through strategic partnerships. Mesoblast’s strong cash reserves ($315M) enable simultaneous product development with future revenues expected from milestone payments, distribution arrangements and direct sales. www.mesoblast.com
MiMedx® is the premier processor of regenerative biomaterial products and implants from human amniotic membrane. MiMedx has distributed hundreds of thousands of amniotic tissue grafts worldwide. Profound clinical outcomes have been achieved in therapeutic areas including ophthalmology, spine, wounds, dental, orthopedic, surgery, sports medicine and urology. With this innovative allograft that promotes bioactive healing, MiMedx® believes its intellectual property and proprietary processing technique strategically positions the Company as the leader in this area of regenerative medicine. www.mimedx.com
PCT, a Caladrius Company, is a center of excellence for the optimization, development and manufacture of cell therapies. With proven expertise and more than 15 years of cell therapy-focused experience, PCT supports the advancement of its clients’ technologies and clinical development programs by mitigating the risks of product development and providing efficient, cost-effective, custom manufacturing solutions, effectively accelerating time to market. PCT’s diverse client base includes leading biotech, pharmaceutical and academic research institutions. It is the only cGMP-compliant cell therapy manufacturing provider with facilities on both the East and the West Coasts of the United States, as well as the only one to see a client’s cell therapy product receive approval from FDA for commercial sale. www.pctcaladrius.com
Scottish Development International (SDI) is Scotland’s agency for economic development. Scotland’s stem cell and regenerative medicine cluster delivers a ”one-stop” solution for companies developing applications at preclinical, clinical or commercial stages of development. This dynamic commercial and academic landscape provides unique solutions across the whole supply chain including cell line supplies, screening, characterization, GMP manufacturing, QA/QC and a range of enabling technologies and other supporting services. Scotland has a proven track record in implementing cell therapy clinical trials using the world-class MHRA-accredited GMP ATMP manufacturing facilities for Phase I and II embryonic and adult stem cells. All of this expertise is in close proximity across Scotland with excellent connections to the rest of Europe. This makes Scotland the ideal location for academic research collaborations, stem cell technology research and development, clinical/translational research and cell line manufacturing. www.sdi.co.uk
The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian not-for-profit, public-private consortium funded by the Government of Canada’s Networks of Centres of Excellence program, six Ontario-based institutional partners and more than 30 companies representing the key sectors of the regenerative medicine industry. CCRM supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. The office, located at the Banting Institute at the University of Toronto, has a 6,000 square foot development facility that houses three platforms: Cell Reprogramming and Engineering; Cell Manufacturing; and, Biomaterials and Devices. A network of academics, industry and entrepreneurs, CCRM translates scientific discoveries into marketable products for patients. CCRM launched in Toronto’s Discovery District on June 14, 2011. www.ccrm.ca
CellGenix is a premium supplier of high-quality reagents and tools for cell therapy and regenerative medicine. Our cytokines and serum-free media are manufactured in accordance with the relevant GMP guidelines. The products are suitable, safe and reliable to be used as ancillary materials in clinical ex vivo cell culture. CellGenix offers a comprehensive product portfolio for the seamless transition from research to commercialization: Serum-free media for the cultivation of dendritic cells, hematopoietic stem cells, T-cells, NK cells and mesenchymal stem cells; Preclinical grade and GMP grade cytokines for optimal growth support and/or differentiation of hematopoietic stem and progenitor cells, as well as dendritic cells, T-cells, NK cells, MSC, ESC and iPS cells; and FEP Bioprocessing containers with unique properties for cell culture and cryopreservation.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide including points-of-care, CROs, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments.
EMD Millipore, a division of Merck KGaA, Darmstadt, Germany, offers solutions that enable scientists to conduct life science research easily, efficiently and economically. With a range of stem cell products, services and dedicated experts, EMD Millipore serves as a strategic partner to customers and helps advance stem cell science. We are deeply committed to providing novel cell culture systems and characterization tools to meet your needs from stem cell research to cGMP manufacturing. Our highly validated, optimized products provide convenient solutions to many cell culture challenges, so you have the time to focus on your research and clinical goals. www.emdmillipore.com
Fresenius Kabi is a leading global healthcare company that focuses on pharmaceuticals and medical devices used to care for critically and chronically ill patients. Through our recent acquisition of Fenwal, we bring over 60 years of experience advancing the fields of cell collection and separation with a deep expertise in closed-system processing. We recently launched Lovo, the only cell processing system that washes and concentrates white blood cells using filtration technology, specifically to serve the needs of the cellular therapies community. Fresenius Kabi’s U.S. headquarters are located in Lake Zurich, Illinois. www.fresenius-kabi.us/lovo
Histogenics was incorporated in 2000 with an initial focus of developing products that meaningfully improve the lives of patients with defects in cartilage and joints. In May 2011, the Company acquired ProChon Biotech, a privately-owned biotechnology company based in Israel, which enabled a synthesis of products, technology and materials science by establishing a robust scientific and technology platform targeting tissue repair solutions. Histogenics’ goal is to become a leading regenerative medicine company developing, marketing and commercializing products in the musculoskeletal segment of the marketplace. The Company is building its core technology platform and plans to expand its clinical products’ therapeutic applications to develop new and innovative solutions for musculoskeletal conditions. Histogenics leverages a combination of the latest advances in molecular biology and proprietary materials sciences to create products designed to help improve patient outcomes. www.histogenics.com
At Janssen Research & Development we are united and energized by one mission—to discover and develop innovative medicines that ease patients’ suffering, and solve the most important unmet medical needs of our time. As one of the Janssen Pharmaceutical Companies of Johnson & Johnson, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in oncology, immunology, neuroscience, infectious diseases and vaccines and cardiovascular and metabolic diseases. www.janssenrnd.com
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. www.lonza.com
Medpace is a global full-service Clinical Research Organization (CRO) providing comprehensive development services for drug, biologic and device programs. Medpace has strong experience supporting development programs for regenerative medicine products across a number of therapeutic areas including cardiovascular, neuroscience, musculoskeletal and diabetes. With extensive medical expertise, a renowned regulatory affairs department and direct global operations in over 40 countries, Medpace conducts studies and navigates regulatory requirements worldwide. From feasibility, research site compatibility, safety and logistics, Medpace brings efficiencies and operational excellence to regenerative medicine development programs. In addition, Medpace offers integrated imaging and lab capabilities through its family of companies to provide cohesive, streamlined and standardized trial management. www.medpace.com
Organovo designs and creates functional, three-dimensional human tissues for use in medical research, cosmetic and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, cosmetic and academic partners. Organovo’s 3D human tissues have the potential to accelerate the discovery process, enabling drug treatments and active agents to be developed faster and at lower cost. The Company recently launched its exVive3D™ Liver for use in toxicology and other preclinical drug testing. We work across a number of disease areas in multiple tissue types with market leaders in the pharmaceutical and cosmetic industries. www.organovo.com
StemBioSys, based in San Antonio, Texas, is a privately-held biomedical company focused on the isolation, growth and delivery of adult stem cells for clinical use. Its patented and proprietary technology platforms – licensed from the University of Texas Board of Regents – overcome key obstacles to creating clinically useful stem cell therapies. The centerpiece of these enabling technologies is the HPMETM (High Performance Micro Environment™) platform. This cell derived three-dimensional microenvironment allows a variety of stem cells to replicate more rapidly and with greater preservation of stem cell properties compared to more traditional tissue culture substrates. This disruptive technology is positioned to transform and improve the methods and cost of isolating, growing and delivering various stem cell populations for applications in research, therapeutic applications and drug discovery. We are currently ramping up GMP production of the core HPME product in preparation for proof of concept testing in various applications. www.stembiosys.com
Clontech Laboratories, Inc. is a wholly owned subsidiary of Takara Bio, Inc. that manufactures and distributes life science research reagents including SMARTer® cDNA synthesis kits for next-generation sequencing; qPCR and PCR reagents; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. Cellartis, a subsidiary of Takara Bio, is a leader in stem cell products and services for drug discovery, toxicity testing and applications within regenerative medicine. Takara Bio is a world leader in biotechnology research and development, with particular strengths in PCR, enzyme systems and protein expression. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene- and cell-based therapy and agricultural biotechnology. Together with its subsidiaries, Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. www.clontech.com
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. www.terumobct.com
Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing and delivery techniques, as well as process development and production. The Company’s pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis, Friedreich’s ataxia and Huntington’s disease. Voyager has broad strategic collaborations with Genzyme, a Sanofi company, and the University of Massachusetts Medical School. Voyager was founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience. The Company is headquartered in Cambridge, Ma. www.voyagertherapeutics.com
Los Angeles-based Capricor Therapeutics is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and large molecule products for the treatment of diseases. Capricor’s lead product candidate, an allogeneic cardiosphere-derived cell (CDC) product, CAP-1002, aims to attenuate and potentially improve damage to the heart caused by a heart attack, and is currently under evaluation in the Phase I/II ALLSTAR clinical trial of patients 30-days to 1-year after a heart attack. Additionally, Capricor plans to explore development of exosome technology as a next generation regenerative medicine platform in a variety of cardiovascular and non-cardiovascular areas. Groundbreaking preclinical research has demonstrated that exosomes extracted from Capricor’s CDCs reduced scar tissue caused by a heart attack and prompted myocardial regeneration in preclinical models of ischemic heart disease. www.capricor.com
A pioneer in newborn stem cell collection and cryopreservation, Cord Blood Registry® (CBR®) believes in the power of stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future. Founded in 1994, CBR is entrusted by parents with storing more than 500,000 hematopoietic and mesenchymal stem cell units. CBR is dedicated to advancing the clinical application of newborn stem cells by partnering with leading research institutions to establish FDA-regulated clinical trials for conditions that include: Autism: Sutter Neuroscience Institute; Cerebral palsy: Georgia Regents University and University of Texas Health Science Center at Houston; Hearing loss: Florida Hospital for Children; Pediatric stroke: Florida Hospital for Children. With the growing number of investigational regenerative therapies, there are now even more potential uses for newborn stem cells. CBR has released more stem cell units for treatments over the last four years than it did during the company’s first 16 years. In 2014, CBR released on average one cord blood sample per week, with 90% being used for regenerative applications. CBR is AABB accredited, FDA-registered, and CLIA certified.
Since its beginnings, Celgene has experienced tremendous growth and geographic expansion. The Celgene of today is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives, reducing the burden on healthcare systems and helping economies grow. Today, Celgene employs world-class biopharmaceutical talent across the globe, and for all of its growth and expansion, Celgene remains true to its DNA – a genetic heritage based on a promise that runs from generation to generation. A promise to support, nurture and create medical innovation, to think differently, to disrupt, to be bold, to be agile and to persevere. It is a promise to change the course of human health while always putting patients first. www.celgene.com
Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, cGMP facilities and international track record makes Cognate one of the most experienced contract manufacturers of cell based products in the world today. www.cognatebioservices.com
CTI Clinical Trial & Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization, with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in solid organ and stem cell transplantation, immunology, infectious disease, hematology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, Ohio, CTI has offices in North America, Europe and South America. www.ctifacts.com
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify and develop strategic relationships. Our conferences, run with the support of leading corporations and international trade associations, include BIO-Europe®, BIO-Europe Spring®, BioPharm America™, EuroMedtech™, BioEquity Europe, ChinaBio® Partnering Forum, The Global Impact Forum™ and Biotech Showcase™. EBD Group’s sophisticated web-based partnering service, partneringONE®, also powers numerous third-party events, and partnering360® is the online community of life science executives that enhances dealmaking productivity year round. www.ebdgroup.com
GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The Company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec’s lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus on opportunities to license our proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. www.genvec.com
MEDIPOST’s research and development is focused on providing novel therapeutics for patients using umbilical cord blood-derived stem cells for osteoarthritis (OA), Broncho-pulmonary Dysplasia (BPD) and Alzheimer’s Disease (AD). MEDIPOST’s flagship product, CARTISTEM® for OA has been approved by the regulatory agency in Korea as an allogeneic cell therapy product in 2012 and over 2,300 patients have been treated on market. CARTISTEM® has also successfully completed a Phase I/IIa trial in the U.S. PNEUMOSTEM® for the prevention of BPD (with Orphan Drug Designation in both Korea and the U.S.) is in Phase II and Phase I/II clinical trials in Korea and the U.S., respectively. NEUROSTEM® for AD is in a Phase IIa clinical trial in Korea after successfully completing a first-in-human Phase I trial in Korea with patients suffering from AD.
Through over 20 years of research, experience and understanding, Osiris Therapeutics has led the way in mesenchymal stem cell (MSC) science and the clinical application of cellular therapies. From commercializing its first generation implantable product, Osteocel, to achieving the Company’s initial goal, when founded in 1992, of developing the world’s first approved stem cell drug, remestemcel-L for graft versus host disease, Osiris has written the book on regenerative medicine. Today, as the leading stem cell company, Osiris continues to address unmet medical needs with innovative approaches in developing and marketing products in wound care, orthopedics and sports medicine. Never forgetting that our products are differentiated by scientific excellence, Osiris’ current product line includes Grafix® for acute and chronic wounds, Cartiform®, a viable cartilage mesh for cartilage repair, and OvationOS®, a viable bone matrix used for bone repair and regeneration. www.osiris.com
TiGenix, founded in the year 2000 to clinically develop and bring to market novel cell therapeutic products, is the only European cell therapy company that benefits from the combination of top-line sales (through its marketed product ChondroCelect) and long term growth potential through its pipeline of adipose-derived stem cell products. TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the EMA. Its lead candidate is Cx601, currently finalizing the recruitment of a single pivotal Phase III in Europe for complex perianal fistulas in Crohn’s patients. The results are expected Q3 2015 and filing for approval in Europe in the first half of 2016. After a successful end of Phase II meeting with the FDA, the Company will file for an SPA before the end of 2014 for the second pivotal trial that will allow for a BLA filing. TiGenix announced recently the clinical development of Cx611, its intravenous-administered allogeneic stem cell product, in early rheumatoid arthritis and severe sepsis. www.tigenix.com
The cell therapy community is charged with the exciting and complex task of delivering novel therapeutics to patients that are safe, efficacious and affordable. Founded in 2012, TrakCel was established with the primary aim of integrating the cell therapy supply chain for autologous and allogeneic therapies to deliver safe, scalable and affordable products. Developed in partnership with major industry players, we have delivered a world-leading cell therapy supply chain solution that gives you the visibility and control required to safely scale-up and scale-out cell-based therapies. Our expertise ensures we provide our customers with solutions that meet their needs today and a technology and delivery framework that ensures we can adapt to their future needs. www.trakcel.com
WuXi AppTec supports the contract development and cGMP manufacture of allogeneic and autologous cell-based therapeutics from concept to commercialization. Our fully-integrated service platforms span from process development to biological safety testing and release. A combination of state-of-the-art facilities, expertise and service options provide clients a unique, single-source solution. Services include: GMP/GTP manufacturing/aseptic processing, process development, GMP cell banking and cell line characterization, analytical (e.g., flow cytometry) and adventitious agent testing (e.g., sterility, bioburden, mycoplasma and virus detection) for lot release and stability, biodistribution, toxicology, biocompatibility, package integrity testing, shipping/cleaning validations and environmental monitoring. www.wuxiapptec.com
Biocom is a member driven organization providing unmatched opportunities and resources to help life science companies and their employees fulfill their business goals and improve life through advancements in health, energy and agriculture. Biocom offers member companies meaningful access to the influential drivers propelling the industry forward across all major life science sectors, including biotechnology, pharmaceutical, diagnostic, medical device, connected health, agriculture and bio-renewable energy. As a company’s most valuable and trusted partner, Biocom provides a tremendous range of initiatives and programs in public policy, capital development, group savings, professional network building and talent development. Biocom serves Southern California, a region offering the perfect climate for life science innovation because of its uniquely collaborative spirit, high concentration of world-class research institutions and its strong foundation for new company creation and development. www.biocom.org
The Life Sciences Report features investment ideas in regenerative medicine, biotechnology, pharmaceuticals, neuroscience, medical devices and tools and diagnostics. We use a simple formula for our success: Credibility + Reach = Exceptional Exposure. The Life Sciences Report reaches institutional and retail investors with expert commentary from many of the most knowledgeable and prestigious experts in the life sciences industry. Names like Jason Kolbert of Maxim Group and Reni Benjamin of H.C. Wainwright to name just a few. Our original content is so highly accepted and credible, that it is categorized and downloaded as research for portfolio managers on the private institutional investing platforms of Bloomberg, Thomson Reuters and FactSet. We average nearly 300 institutions downloads for every article we publish. In addition, The Life Sciences Report has more than 35,000 subscribers, 60,000 twitter followers and syndicates to more than 300 major newswires and blogs. The Life Sciences Report provides investor exposure you can’t get anywhere else. www.thelifesciencesreport.com
“Overall the Stem Cell Meeting on the Mesa has now become one of our favorite meetings in the cell therapy space. The combination of quality attendees, discussions, partnering software and venue were fantastic.”